Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.45. Hemispherx BioPharma shares last traded at $0.42, with a volume of 173,398 shares trading hands.
Hemispherx BioPharma Trading Up 3.8 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than Hemispherx BioPharma
- Investing In Automotive Stocks
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- The Significance of Brokerage Rankings in Stock Selection
- 3 Value Stocks You Can Buy Before They Become Big
- 3 Fintech Stocks With Good 2021 Prospects
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
